Table 2.
List of the therapeutics, their targets and their progressions through clinical trials
| Name | Target | Clinical trial progression? |
|---|---|---|
| ADH-1 | CDH2 | Phase II (solid tumours) |
| AZD2014 | mTORC1 and mTORC2 | Phase II (solid tumours) |
| AZD8055 | mTORC1 and mTORC2 | Phase I (halted development) |
| BEZ-235 | PI3K and mTOR | Phase I (ALL), phase II (solid tumours) |
| Buparlisib | PI3K | Phase I |
| Capmatinib | Wnt | Pre-clinical |
| Compound 15 | CDH2 | Pre-clinical (solid and haematological cancers) |
| Dasatinib | Tyrosine kinase | FDA-approved for paediatric chronic myeloid leukaemia |
| Dexamethasone | Glucocorticoid receptors | FDA-approved |
| Everolimus | mTOR | FDA-approved (solid tumours) |
| Idelalisib | PI3K-δ | FDA-approved for chronic lymphocytic leukaemia |
| Imatinib | Tyrosine kinase | FDA-approved for chronic myeloid leukaemia |
| Isoquercitrin | Wnt | Pre-clinical |
| IWP-4 | Wnt | Pre-clinical |
| XAV-939 | Wnt | Pre-clinical |
| Venetoclax (ABT-199) | BCL-2 | FDA-approved for AML |